October 2016


In this Supplement

RevELUTIONizing Drug-Eluting Technologies

How drug-eluting therapies are shaping a new era of endovascular interventions.




Download a PDF of this supplement

Complexity of SFA Disease Is Driving the Need for Dual Therapy

A discussion of potential differential indications for drug-eluting devices.

By Prof. Thomas Zeller, MD

The Future of Antiproliferative Therapies for Endovascular Interventions

Translational findings from the Ranger Paclitaxel-Coated Balloon data.

By Renu Virmani, MD, FACC

Renu Virmani, MD

President CV Path Institute

See Dr. Renu Virmani and Dr. Juan Granada discuss the future of drug-eluting technologies

The Science Behind Local Drug-Delivery Technologies: The Benefit of Sustained Paclitaxel Release in the SFA

Sustained drug release is key to maintaining biological effect.

By Juan F. Granada, MD, FACC

Juan Granada, MD

Executive Director CRF Skirball Center for Innovation

See Dr. Juan Granada discuss the importance of sustained drug release

Patterns of Restenosis: What Are the Data Telling Us?

With Michael R. Jaff, DO

Ranger Paclitaxel-Coated PTA Balloon Catheter Clinical Update

Recent early data from two studies demonstrate the promise of the Ranger DCB.

Sustained Drug Release Optimizes Long-Term Outcomes

Is the drug-eluting vascular stent a game-changer?

By Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA

Are DCBs a Durable Solution?

A discussion of DCB durability and superiority in the context of 2-year data.

By Gary M. Ansel, MD

The Future of Drug-Eluting Therapies: What Will the Treatment Algorithm Look Like?

By William A. Gray, MD

Global Perspectives on Drug-Eluting Technologies

With Prof. Thomas Zeller, MD; Antonio Micari, MD, PhD; Konstantinos Katsanos, MSc, MD, PhD, EBIR; and Yann Gouëffic, MD, PhD

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.